D. E. Shaw & Co., Inc. Black Diamond Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $125 Billion
- Q2 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 17,900 shares of BDTX stock, worth $71,600. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,900
Previous 17,854
0.26%
Holding current value
$71,600
Previous $27,000
62.96%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding BDTX
# of Institutions
98Shares Held
41.3MCall Options Held
0Put Options Held
0-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.5MShares$42 Million0.02% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$22.4 Million0.73% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$17.8 Million0.91% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$12.9 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.73MShares$10.9 Million0.15% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $145M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...